Purpose of Review Idiopathic REM sleep behavior disorder (iRBD) is one of the most significant prodromal manifestations of synucleinopathies. Different predictive biomarkers for iRBD conversion have been investigated, but scarce data are present in literature about the predictive role of cerebrospinal fluid (CSF) biomarkers. In this review, we focus on CSF biomarkers in patients with both iRBD and RBD associated with synucleinopathies to explore their potential predictive power. Recent Findings Recent studies revealed that CSF α-synuclein levels are higher in Parkinson's disease (PD) patients with RBD compared to those without RBD, even if α-synuclein does not seem to predict conversion of iRBD into PD. In the Parkinson Progression Marker Initiative (PPMI) cohort, early PD patients with RBD show lower CSF Aβ 42 levels, which predict faster cognitive decline. CSF prion protein and inflammatory biomarkers have been also investigated in RBD and synucleinopathies with controversial results. Summary A variety of CSF biomarkers are promising candidate for predicting iRBD conversion into synucleinopathies. Further studies are needed in iRBD patients followed for several years in order to observe the phenoconversion in synucleinopathies and to elucidate the possible role of CSF biomarkers as predictive biomarkers of conversion.
Introduction
Rapid eye movement (REM) sleep behavior disorder (RBD) is a sleep disorder featured by enacting dreams associated with the loss of muscle atonia during REM sleep. When occurring isolated, it has been defined as idiopathic RBD (iRBD), a condition in which RBD is not associated with other neurologic disorders; on the other hand, symptomatic (or secondary) RBD indicates the presence of RBD associated with other neurologic disturbances such as narcolepsy or neurodegenerative diseases, and in particular synucleinopathies. However, it is now well ascertained that iRBD represents a potential harbinger of neurodegenerative disorders, in particular synucleinopathies including Parkinson's disease (PD), multisystem atrophy (MSA), and dementia with Lewy bodies (DLBs). The association between RBD and synucleinopathies is mainly due to the impairment of specific brainstem areas, especially mesencephalon and pontine tegmentum, which are involved in the pathogenesis of both conditions [1] . Although the diagnosis of PD is centered on cardinal motor signs, α-synuclein-pathology starts several years before the occurrence of motor symptoms. Hence, the concept of prodromal or premotor stages of PD have been recently introduced to define the stages in which patients present early clear non-motor symptoms but subtle motor signs, which are not sufficient to meet the current diagnostic criteria for PD [2] . Converging evidence indicates that iRBD is the most specific prodromal symptom of α-synucleinopathies; the great majority of patients initially diagnosed as iRBD eventually develop a Lewy body disorder during the following years [3] . The prodromal phase of α-synucleinopathies is of great interest, relating to the possible development of disease-modifying and neuroprotective therapies, which should be introduced as earliest as possible. Accordingly, validation of specific markers for prodromal illness represents a key challenge and several efforts have been made to identify biomarkers predicting the conversion of iRBD into synucleinopathy. Hence, in this review, we will put our attention on CSF biomarkers in RBD, highlighting their potential ability to predict conversion of iRBD in synucleinopathies.
REM Sleep Behavior Disorder
RBD belongs to sleep parasomnias, which are defined as sleep disorders characterized by undesirable physical events or experiences occurring in association with sleep (at sleep onset, during sleep, or after arousal from sleep). Parasomnias are divided in two main groups represented by non-REM (NREM) sleep parasomnias (including sleepwalking, sleep terrors, and confusional arousals) and REM sleep parasomnias; among them, RBD is the most representative. It consists of loss of muscular atonia during REM sleep (the so-called REM sleep without atonia, RSWA), associated with a history of nocturnal distressing dreaming and complex behavior [4] . Although a series of specific questionnaires have been validated to detect RBD among general population [5] , its diagnosis relies on video-polysomnography (vPSG). According to the 3rd Edition of International Classification of Sleep Disorders [6] , diagnosis of RBD requires the presence of RSWA on nocturnal vPSG, in association with sleep-related injurious (or potentially injurious) abnormal and vigorous nocturnal complex motor behaviors and vocalizations, either derived by history or documented during a single night of vPSG [6] . iRBD is considered a rare disease and its prevalence has been estimated between 0.38 and 0.5% in large populationbased studies [7] . Moreover, it is a male predominant disorder, usually diagnosed between 50 and 85 years old [8] .
The circuitry involved in RBD is not fully understood. However, different brain areas including the primary and premotor cortices with their input from basal ganglia, brainstem, and spinal cord motor generators seem to be involved [9] . Briefly, two motor systems, present in the region of midbrain and pons, are implicated in REM sleep muscle atonia: the sublaterdorsal nucleus in the "REM-on" region (it actives two inhibitory pathways, the "direct route" and the "indirect route," both inhibiting the motor neurons) and the locomotor generators, not yet identified in humans, responsible for suppressing locomotor activity. These brain regions appeared to be dysregulated in animal models of RSWA and thus can underline the clinical disorder [9] .
RBD as Prodromal Feature of Synucleinopathies
Evidence deriving from different cohort studies indicates that iRBD is one of the most relevant predictor of synucleinopathies. Shenck and co-authors [3] showed that a very high percentage (about 81%) of patients initially diagnosed as iRBD eventually developed a parkinsonism/dementia syndrome, mainly PD and DLB, and less frequently MSA. The risk of developing synucleinopathy increases along the follow-up, with a rate of conversion ranging from 33% after a 5-year follow-up to 91% after a 14-year follow-up [10] . However, it has been reported that time interval between iRBD and subsequent neurodegenerative disorder can range up to 50 years, suggesting that α-synuclein pathology starts several decades before the appearance of the first subtle symptoms of PD, MSA, and DLB [11] . Findings suggest that iRBD patients, even when remaining clinically free from synucleinopathies, show the decreased striatal dopamine transporter (DAT) uptake on [123]I-FP-CIT SPECT or the appearance of substantia nigra (SN) hyperechogenicity on transcranial sonography during the follow-up, suggesting the future development of synucleinopathy [12] .
Nevertheless, it should be mentioned that only a quarter of PD patients manifests RBD before the occurrence of parkinsonism, another quarter tends to have a simultaneous onset of RBD and parkinsonism, and the remaining 50% develops REM parasomnia once motor disturbances have already manifested [13] . A possible explanation for this heterogeneity is that RBD is associated with specific motor phenotype, and it has been found to occur earlier and more frequently in patients with postural instability/gait difficulty phenotype [14] .
As reported by a recent meta-analysis [15] , the prevalence of RBD has been estimated up to 88% in MSA and more than half of patients reported symptoms of RBD before the onset of motor deficits. In DLB, RBD is a part of core clinical features since it has been discovered to improve the diagnostic accuracy of autopsy-confirmed DLB. Moreover, RBD starts several years before the occurrence of other symptoms and tends to become less vigorous or even quiescent over time [16] .
Predictive Biomarkers for Conversion of iRBD in Synucleinopathies: State of the Art
Patients with iRBD can develop a variety of other early nonmotor symptoms, which do not fulfill the current diagnostic criteria for synucleinopathies but suggest that the underlying neurodegenerative process has already started. iRBDassociated non-motor symptoms include olfactory loss, autonomic dysfunction, impaired color vision, constipation, depression, and cognitive impairment. Longitudinal studies revealed that, among them, impaired olfaction and impaired color vision are the most powerful predictor for conversion of iRBD into synucleinopathies [17, 18••, 19] .
Imaging of nigro-striatal dopaminergic pathway can provide information about RBD conversion. On 99mTc-TRODAT-1 SPECT, iRBD patients presenting lower DAT density in the putamen have shorter conversion-free survival time [20••] . Meanwhile, on [123]I-FP-CIT, a DAT deficit greater than 25% in the putamen is able to define iRBD patients with higher risk to develop synucleinopathies along a 3-year follow-up (see Table 1 ) [21••] .
SN hyperecogenicity on transcranial sonography, if used in association with [123]I-FP-CIT, increases the sensibility of detecting iRBD patients converting in synucleinopathies up to 100%, whereas the sensitivity of baseline SN hyperechogenicity alone is near 43% (see Table 1 ) [22] .
Studies based on electroencephalography revealed that iRBD patients developing a neurodegenerative disorder present greater delta and theta frequencies compared to patients with iRBD and synucleinopathy-free [23••] .
Magnetic resonance imaging (MRI) techniques, especially resting-state functional MRI and 7-T susceptibility-weighted imaging, have been studied, but, to date, it does not seem to play a specific role for predicting phenoconversion of patients with iRBD [24, 25] .
CSF Biomarkers in Synucleinopathies: an Overview
It is now well accepted that CSF, strictly in contact with neurons, is a source of biomarkers potentially offering the most promising insight into the pathogenesis of neurodegenerative disorders since their early stages. CSF has been extensively investigated in terms of both diagnostic and prognostic value in synucleinopathies, considering several biomarkers.
α-Synuclein is a cytosolic protein widely expressed in brain and mostly localized in presynaptic neuronal terminals where it acts as a mediator of neurotransmitters release, vesicle trafficking, and synaptic plasticity [25] . It is the major component of Lewy bodies, the most representative pathological hallmark of synucleinopathies. After its discovery in the CSF, the role of α-synuclein as a biomarker of synucleinopathies has been largely investigated. Different studies revealed that CSF total α-synuclein (t-α-syn) levels are decreased in synucleinopathies compared to other neurodegenerative disorders and to healthy subjects, maybe reflecting higher brain levels of pathological deposition of α-synuclein in Lewy bodies, similar to pathological "protein trapping" reported for β-amyloid 42 (Aβ 42 ) in Alzheimer's disease (AD) [26] [27] [28] [29] [30] . Furthermore, it was found also that both CSF oligomeric α-synuclein (o-α-syn) levels and o-α-syn/t-α-syn ratio are higher in PD patients compared to healthy controls [30, 31] . A similar trend was observed for phosphorylated α-synuclein (p-α-syn), showing higher CSF levels in PD patients compared to healthy controls [32] . Postmortem CSF p-α-syn was found significantly raised in MSA, distinguishing it from other synucleinopathies [33] . When CSF α-synuclein levels were studied in relation to clinical features, lower CSF t-α-syn and higher o-α-syn levels were detected in the more advanced stages of PD [34, 35] .
The coexistence of amyloid plaques and neurofibrillary tangles with Lewy bodies in synucleinopathies [36] is one of the main reasons that have led researchers to investigate core AD biomarkers (total tau, t-tau; phosphorylated tau, p-tau; and Aβ 42 ) even in the CSF of patients affected by synucleinopathies. Several studies highlighted the prognostic value of Aβ 42 in terms of development of cognitive impairment: lower CSF levels strongly predict greater and faster cognitive decline in PD patients [37] [38] [39] . Although the controversial results, a similar association has been found for t-tau and p-tau, showing higher CSF levels in PD demented patients compared to non-demented patients [40•] . Furthermore, Aβ 42 /t-tau ratio improved the diagnostic accuracy of PD patients from controls [30] .
In the last few years, besides α-synuclein and core AD biomarkers, different CSF biomarkers have been investigated in synucleinopathies, often with uneven and variable results. They include markers related to genetic forms of PD (i.e., DJ-1 and GCase activity) [30, 41] , markers of inflammation [42] , and markers of neuronal injury other than protein tau such as neurofilament light chain (NfL) [43, 44•] .
In Table 2 , the results of CSF biomarker studies in PD patients with RBD compared to those without RBD are briefly reported.
CSF Biomarkers in RBD α-Synuclein
In the last years, researchers have compared CSF levels of biomarkers in PD patients with and without RBD, often showing inconclusive and controversial results. Hu and collaborators [45•] , by using the REM Sleep Behavior Disorders Screening Questionnaire (RBDSQ), divided a cohort of PD subjects in patients with and without RBD and found that patients with RBD showed higher CSF and serum levels of o-α-syn compared to patients without RBD. They found also that RBDSQ score increased concomitantly with higher CSF o-α-syn levels. Accordingly, Dolatshahi and colleagues [46] recruited 112 non-demented PD patients from the Parkinson Progressive Marker Initiative (PPMI), a 5-year observational, multi-center, and international study encompassing 400 recently diagnosed drug-naïve PD patients. They identified greater increase of CSF α-synuclein levels after 1-year follow-up in patients with RBD compared to those without RBD. Meanwhile, in the Fox Investigation for New Discovery of Biomarkers in Parkinson's Disease (BioFIND), a cross-sectional and observational study assessing clinical features and CSF biomarkers of 115 moderate and advanced PD, CSF α-synuclein levels did not correlate with RBD questionnaire total score [49] .
Nevertheless, only a very limited number of studies have been performed in patients manifesting RBD as prodromal feature without evidence of motor signs. Compta and colleagues [40• ] measured CSF α-synuclein levels in healthy controls, iRBD patients, non-demented PD patients (NDPD) and demented PD patients (PDD) with the purpose of reflecting the prodromal-motor-dementia continuum of PD. Whereas both total α-synuclein and oligomeric/ total ratio did not significantly differ among groups, o-α-syn showed higher levels in both PD and PDD patients compared to iRBD patients and controls. However, the lack of differences between iRBD and controls did not allow to consider α-synuclein, a prodromal marker of PD in patients with RBD.
CSF AD Biomarkers
Core AD CSF biomarkers have been studied in RBD in a lesser degree compared to α-synuclein. The great majority of the available studies do not present significant associations between RBD and CSF levels of AD core biomarkers [46, 49] .
However, more recently, Pagano and collaborators measured CSF biomarkers in a large group of drug-naïve early PD patients, showing that patients with RBD had lower CSF Aβ 42 and greater t-tau/Aβ 42 ratio compared to patients without RBD [47•] . Interestingly, they found that the severity of RBD correlated with higher amyloid pathology as proved by lower CSF Aβ 42 concentrations. Furthermore, their findings revealed also that severity of RBD at baseline was predictive for faster cognitive decline in PD patients presenting both greater amyloid and greater α-synuclein pathologies. Accordingly, in the PPMI cohort CSF Aβ 42 levels were significantly lower at baseline in early PD patients with RBD. After 3 years, PD patients with RBD had greater cognitive decline in Montreal Cognitive Assessment (MoCA) score, and lower baseline Aβ 42 levels were able to predict cognitive decline only in PD subjects with RBD over the 3-year followup [48•] .
Prion Protein (PrP)
Mainly expressed in neurons and microglia, prion protein (PrP) is a membrane-binding glycoprotein which is involved in molecular pathways contributing to neuronal differentiation and synaptic development, to cellular oxidative stress response, and to cell-cell adhesion. Some evidence indicates that CSF PrP levels are altered in different neurodegenerative disorders [50] . To date, however, few studies assessing CSF PrP in patients presenting synucleinopathies and RBD have been carried out. Particularly, Zhang and collaborators [51] showed that CSF PrP levels were increased in PD patients with RBD compared to those without RBD, suggesting therefore an accelerated neuronal degeneration in RBD.
Inflammatory Markers
In their works, Hu and colleagues [45•] found that CSF nitric oxide (NO), CSF interleukin 1β (IL-1β), and serum prostanglandin E2 (PGE2) levels were higher in PD patients with RBD compared to patients without RBD. Moreover, RBDSQ score increased concomitantly with higher levels of these inflammatory biomarkers. They showed also that CSF o-α-syn levels significantly correlated with CSF NO, IL-1β, and necrosis tumor factor 1 (TNF1) levels in patients with RBD, suggesting a condition of increased microglia activation in the presence of elevated o-a-synuclein CSF levels in the pathophysiology of RBD. Accordingly, in a recent casecontrol study based on PET imaging and involving a series of patients with iRBD and without clinical evidence of parkinsonism and cognitive impairment, increased microglial activation was detected in the substantia nigra along with reduced dopaminergic function in the putamen [52••] . Furthermore, an interesting correlation between CSF inflammatory markers, α-synuclein, and markers of neuroaxonal injury (i.e., NfL) has been recently evidenced [50] . Taken together, these findings indicate that neurodegeneration and neuroinflammation are two early and complementary aspects, which interact each other in the pathological network leading to synucleinopathies. Hence, besides α-synuclein, markers of inflammation and neuroaxonal injury may represent the future direction in the research focusing on serum and CSF biomarkers in patients with RBD as prodromal feature of PD and other synucleinopathies.
Conclusions
Different biomarkers have been investigated for their ability of predicting iRBD phenoconversion into synucleinopathies, so far. They include clinical biomarkers, imaging of nigro-striatal dopaminergic pathway, hyperecogenicity of the SN, brain MRI, and electroencephalography. CSF biomarkers have been explored in patients with synucleinopathies, especially PD, manifesting RBD or not. In PD, significant differences have been evidenced for α-synuclein, core AD biomarkers, prion protein, and inflammatory biomarkers between patients with RBD and those without RBD. However, the role of CSF biomarkers as predictor of iRBD conversion remains to be defined. The validation of specific CSF biomarkers able to predict the development of synucleinopathies in patients with iRBD is still an unmet need. Based on Lewy body pathology, α-synuclein seems the most promising biomarker for predicting the conversion to alphasynucleinopathies in iRBD patients. Moreover, the coexistence in synucleinopathies of amyloid plaques and neurofibrillary tangles with Lewy bodies makes core AD biomarkers interesting as predictive biomarkers of iRBD conversion. Accordingly, CSF Aβ 42 levels can be used for predicting the cognitive decline in patients affected by iRBD and possibly developing the Lewy body dementia disorders. Meanwhile, the ascertained role of neuroinflammation in neurodegenerative disorders suggests to consider even inflammatory markers and markers of neuronal injury as potential predictive biomarkers.
Further studies should be carried out in patients with iRBD to define the role of CSF biomarkers as predictors of conversion. Longitudinal studies reflecting the prodromal and clinical continuum of synucleinopathies will be extremely useful to elucidate the sensitivity, specificity, reliability, and effect of confounding factors of these biomarkers. Accordingly, CSF biomarkers could gain a prognostic value in patients with iRBD, hopefully predicting the conversion into a specific disease (PD, MSA, or DLB).
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